Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat sodium for severe pulmonary ARDS
ChiCTR2300078686Phase 4Recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of sivelestat in acute respiratory distress syndrome (ARDS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Oxygenation index improvement rate on day 8. Started Dec 2023; status: recruiting.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on ChiCTR2300078686.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300078686.